Sorrento Therapeutics is a biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases. The Company's lead programs consist of four Phase III BioSimilar/BioBetter antibodies. It is also advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).
Type
Public
HQ
San Diego, US
Founded
2006
Size (employees)
154 (est)+59%
Sorrento Therapeutics was founded in 2006 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Sorrento Therapeutics

Henry Ji

Henry Ji

Chairman, President and Chief Executive Officer
Jerome Zeldis

Jerome Zeldis

Chief Medical Officer
George Ng

George Ng

EVP, Chief Administrative and Legal Officer
Dean Ferrigno

Dean Ferrigno

Vice President, Finance

Sorrento Therapeutics Office Locations

Sorrento Therapeutics has an office in San Diego
San Diego, US (HQ)
9380 Judicial Dr
Show all (1)
Report incorrect company information

Sorrento Therapeutics Financials and Metrics

Sorrento Therapeutics Financials

Sorrento Therapeutics's revenue was reported to be $8.15 m in FY, 2016 which is a 77.6% increase from the previous period.
USD

Revenue (Q1, 2018)

6.2 m

Gross profit (Q1, 2018)

4.9 m

Gross profit margin (Q1, 2018), %

79%

Net income (Q1, 2018)

(33.5 m)

EBIT (Q1, 2018)

(32.5 m)

Market capitalization (14-Jun-2018)

682.3 m

Closing share price (14-Jun-2018)

7.4

Cash (31-Mar-2018)

24.3 m

EV

663.5 m
Sorrento Therapeutics's current market capitalization is $682.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

460.1 k3.8 m4.6 m8.2 m

Revenue growth, %

731%20%78%

General and administrative expense

6.3 m10 m20.1 m24.2 m

R&D expense

9 m24 m31.3 m42.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

83.8 k976 k775 k1.3 m977 k1.2 m1.1 m988 k902 k2.2 m4.9 m4.7 m131.4 m6.2 m

Cost of goods sold

3 m1.3 m

Gross profit

128.5 m4.9 m

Gross profit Margin, %

98%79%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

31.7 m71.9 m39 m82.4 m

Current Assets

32.6 m73.9 m141 m89.7 m

PP&E

2.4 m2.3 m7.2 m12.7 m

Goodwill

24 m24 m20.6 m41.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

6.4 m29.9 m50.2 m44.3 m60.5 m51.7 m59.1 m20.8 m98.2 m66.5 m33.9 m53.7 m38.3 m24.3 m

Current Assets

6.9 m31.2 m51.4 m45.8 m62.2 m53.8 m124.8 m71.7 m146.3 m71.8 m42.1 m60.6 m44.7 m36.6 m

PP&E

1.7 m2.4 m2.3 m2.4 m2.5 m2.8 m3.8 m7.4 m9.2 m10.1 m17 m18 m19 m19.5 m

Goodwill

24 m24 m24 m24 m12.5 m20.6 m20.6 m20.6 m20.6 m36.9 m38.3 m38.3 m38.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(21.9 m)(34.7 m)(50.1 m)(63.9 m)

Depreciation and Amortization

1.3 m3.2 m2.4 m2.9 m

Inventories

(3.2 m)

Accounts Payable

878.6 k(497 k)(2.7 m)3.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(10.6 m)(10.1 m)(18.5 m)(26.2 m)(10.4 m)(21.4 m)(23.5 m)(20 m)(66.1 m)14.2 m(23.8 m)(38.5 m)(37.1 m)(33.5 m)

Depreciation and Amortization

637.6 k774 k1.6 m2.4 m823 k1.4 m1.8 m545 k1.1 m1.5 m3.2 m5.3 m2 m

Accounts Payable

824.9 k(980 k)(955 k)(703 k)95 k321 k(352 k)1.8 m3.1 m1.4 m2.4 m(1.1 m)4.6 m(1.8 m)

Cash From Operating Activities

(9.3 m)(9.1 m)(15.5 m)(21.1 m)(8.8 m)(7.6 m)(25.9 m)(20.2 m)(32.4 m)(21.9 m)(41.7 m)(54.3 m)(24 m)
USDY, 2018

EV/EBIT

-20.4 x

EV/CFO

-27.7 x

Revenue/Employee

40.6 k

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information